Short Interest in Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) Grows By 227.3%

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) was the recipient of a significant growth in short interest in May. As of May 15th, there was short interest totaling 50,147 shares, a growth of 227.3% from the April 30th total of 15,320 shares. Based on an average daily trading volume, of 55,256 shares, the days-to-cover ratio is presently 0.9 days.

Ono Pharmaceutical Price Performance

Shares of OPHLY stock traded down $0.05 during mid-day trading on Friday, hitting $4.94. The company had a trading volume of 20,036 shares, compared to its average volume of 26,218. Ono Pharmaceutical has a 52-week low of $3.35 and a 52-week high of $5.75. The stock’s 50 day moving average price is $5.08 and its 200-day moving average price is $4.92.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty?pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.

In oncology, Ono Pharmaceutical is best known for co?developing and commercializing nivolumab (Opdivo), an anti–PD?1 immune checkpoint inhibitor developed in partnership with Bristol?Myers Squibb.